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Barrett's esophagus, a premalignant condition associated with chronic 
gastroesophageal reflux, carries an approximate 40-fold increase in the 
incidence of adenocarcinoma. Between 1975 and 1994, 113 patients with 
Barrett's esophagus underwent antireflux procedures at the Mayo Clinic. 
The antireflux procedure was performed more than 3 months after the 
diagnosis of Barrett's disease in 39 patients (34.5%) and during the initial 
preoperative evaluation in 74 (65.5%). Uncut Collis-Nissen fundoplication 
was performed in 69 patients (61.1%), Nissen fundoplication was per- 
formed in 16 (14.2%), cut Collis-Nissen fundoplication was performed in 12 
(10.6%), Belsey repair was performed in nine (8.0%), Collis-Belsey repair 
was performed in six (5.3%), and Nissen fundoplication with an anterior 
gastropexy was performed in one (0.9%). There was one operative death 
(0.9% mortality). Morbidity occurred in 41 patients (36.3%), including 
cardiac arrhythmia in eight (7.0%), pneumonia in six (5.3%), empyema in 
five (4.4%), hemorrhage in four (3.6%), myocardial infarction in two (1.8%), 
and wound dehiscence, wound infection, perforated uodenal ulcer, and 
postoperative l ak in one each (0.9%). Median follow-up for the 112 
survivors of operation was 6.5 years (range 4 months to 18.2 years). 
Excellent or good alleviation of symptoms was obtained in 92 patients 
(82.2%). Ninety-nine patients (88.4%) are currently alive and 13 (11.6%) 
have died. Three patients (2.7%) subsequently had adenocarcinoma of the 
esophagus after the antireflux procedure at 13, 25, and 39 months; two of 
these died of cancer. The incidence of esophageal carcinoma in this select 
group of patients was one in 273.8 patient-years of follow-up. We conclude 
that although antireflux procedures in patients with Barrett's esophagus 
result in long-term control of reflux symptoms, the possibility of esophageal 
cancer still exists. Endoscopic surveillance should therefore be recom- 
mended. (J Thorac Cardiovasc Surg 1996;111:1135-40) 
B arrett's esophagus (BE) is an acquired condi- tion associated with excessive gastroesopha- 
geal reflux that occurs in approximately 15% of 
patients with reflux esophagitis. 1 Patients with BE 
have a higher incidence of complications of reflux, 
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including stricture, ulceration, and the develop- 
ment of adenocarcinoma. 2 The incidence of car- 
cinoma associated with BE is unknown but has 
been estimated to range from one case per 16 to 
one per 441 patient-years. 3 
BE is thought to arise from exposure of the 
esophageal mucosa to gastric or duodenal secre- 
tions. Consequently, elimination of gastroesopha- 
geal reflux should prevent complications. Antireflux 
operations have seldom been shown to lead to 
regression of the BE, 4-9 however, and the influence 
of antireflux procedures (ARPs) on the develop- 
ment of carcinoma has not been well studied. TM We 
retrospectively reviewed our experience with pa- 
tients with BE who underwent ARPs to determine 
these procedures' effects on the development of 
esophageal denocarcinoma. 
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Table I. Indications for antireflux procedure in 113 
patients with BE 
Indications No. % 
Refractory symptoms 98 86.7 
Nondilatable stricture 40 35.4 
Chronic anemia 13 11.5 
Esophageal ulceration 13 11.5 
Regurgitation with aspiration 11 9.7 
Paraesophageal hernia 11 9.7 
Methods 
Between 1975 and 1994, 1935 patients with BE were 
evaluated at the Mayo Clinic. Of these, 113 (5.8%) 
underwent ARPs. The diagnosis of BE in these 113 
patients was confirmed by esophagogastroduodenoscopi- 
cally directed biopsy, with four-quadrant biopsy samples 
obtained every 2 cm. Our criteria for the diagnosis of BE 
have been previously published; we include patients with 3 
cm or more of columnar epithelium or incomplete intes- 
tinal metaplasia with goblet cells (specialized columnar 
epithelium) in the esophagus, even if less than 3 cm in 
length.11.12 
We retrospectively analyzed each record for age, sex, 
symptoms, diagnostic evaluation, indications for opera- 
tion, operative procedure, functional results, and devel- 
opment of esophageal carcinoma. Annual endoscopic 
surveillance was recommended after operation, and sur- 
veillance biopsy samples were reviewed for the develop- 
ment of dysplasia or carcinoma. After the ARP, functional 
results were considered excellent if the patient was eating 
a general diet without symptoms, good if symptoms were 
minimal and neither medication nor esophageal dilatation 
was required, fair if symptoms were improved but either 
medication or esophageal dilatation was required, and 
poor if symptoms were unchanged orworse. Patients were 
also questioned during follow-up for symptoms of reflux, 
dysphagia, diarrhea, or bloating. Operative mortality in- 
cluded those patients who died within the first 30 days or 
those who died later but during the same hospitalization. 
Freedom from esophageal denocarcinoma was estimated 
by the Kaplan-Meier method, with the date of the ARP 
used as the starting point and the date of detection of the 
adenocarcinoma used as the endpoint. 13
Results 
There were 113 patients (78 men and 35 women) 
with BE who underwent ARPs. Median age at ARP 
was 68 years (range 11 to 92 years). Signs and 
symptoms were present before surgical intervention 
in 109 patients (96.5%) and included heartburn in 
77 (68.1%), regurgitation i 59 (52.2%), dysphagia 
in 56 (49.6%), sternal pressure in 34 (30.1%), aspi- 
ration in 30 (26.5%), and hemorrhage in 15 (13.3%). 
Associated esophageal diseases included sclero- 
derma in four (3.5%) and achalasia in one (0.9%). 
Previous esophageal operations had been per- 
formed in 26 patients (23.0%): previous ARP in 21 
patients, esophagomyotomy in two patients, and 
tracheoesophageal fistula repair, Thal esophagogas- 
tric fundoplication for perforation, and repair of a 
Bochdalek hernia in one patient each. 
All patients underwent esophagogastroduodenos- 
copy. In addition to diagnosing BE, the esophago- 
gastroduodenoscopy demonstrated a diaphragmatic 
hernia in 85 patients (75.2%), esophagitis in 68 
(60.2%), esophageal stricture in 41 (36.3%), esoph- 
ageal ulcer in 41 (36.3%), mucosal nodularity and 
epiphrenic diverticulum in two (1.8%) each, and 
hemorrhage in one (0.9%). An upper gastrointesti- 
nal barium swallow test was performed in 98 pa- 
tients (86.7%) and demonstrated a sliding hiatal 
hernia in 86 (87.8%), esophageal stenosis in 38 
(38.8%), and paraesophageal hiatal hernia in 14 
(14.3%). An esophageal motility test was performed 
in 81 patients and showed a reduced lower esopha- 
geal sphincter pressure in 48 (59.3%), combined 
lower esophageal sphincter pressure and abnormal 
peristalsis in 12 (14.8%), abnormal peristalsis only in 
six (7.4%), achalasia in one (1.2%), and obstruction 
with an inability to pass the catheter in one (1.2%). 
Thirteen patients (16.0%) had normal manometric 
findings. A 24-hour esophageal pH test was per- 
formed in 17 patients with positive results in 15 
(88.2%) and negative results in two (11.8%). All 
patients were initially managed with a medical reg- 
imen consisting predominantly of histamine block- 
ers and, more recently, omeprazole before consid- 
eration of ARP. 
The most common indication for ARP (Table I) 
was the presence of symptoms that were refractory 
to medical therapy in 98 patients (86.7%). Several 
types of ARP were performed uring the duration 
of this study: uncut Collis-Nissen fundoplication i
69 patients (61.1%), Nissen fundoplication in 16 
(14.2%), cut Collis-Nissen fundoplication in 12 
(10.6%), Belsey repair in nine (8.0%), Collis-Belsey 
repair in six (5.3%), and Nissen fundoplication plus 
anterior gastropexy in one (0.9%). The ARP was 
performed at the initial diagnosis of BE in 74 cases 
(65.5%) and more than 3 months after diagnosis in 
the remaining 39 (34.5%). Fifteen patients (13.3%) 
had other concomitant procedures performed ur- 
ing the ARP, including cholecystectomy in four 
cases, pulmonary wedge resection in three, vagot- 
omy in three, antrectomy in two, and tracheotomy, 
planned splenectomy, and appendectomy in one 
case each. 
There was one operative death (0.9% mortality). 
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Cause of death was cardiac arrest. Intraoperative 
complications occurred in six patients (5.3%): sple- 
nectomy, gastrotomy, and esophageal perforation in 
two patients each (1.8%). Postoperative complica- 
tions occurred in 41 patients (36.3%). Major com- 
plications included cardiac arrhythmia in eight 
(7.0%), pneumonia in six (5.3%), empyema in five 
(4.4%), myocardial infarction in two (!.8%), and 
wound dehiscence, wound infection, perforated u- 
odenal ulcer, and esophageal leak in one patient 
each (0.9%). Five patients (4.4%) required early 
reoperation to control hemorrhage in two cases, to 
repair a wound dehiscence in one case, and to repair 
the previously mentioned perforated ulcer and 
esophageal leak in one case each. A postoperative 
water-soluble contrast esophageal swallow test was 
performed in 84 cases (74.3%). Abnormal findings 
included obstruction i  four patients and recurrence 
of a hernia in one. Six patients (5.3%) required 
esophageal dilatation before discharge from the 
hospital. Median hospitalization was 9 days (range 4 
to 83). 
Follow-up was complete for all 112 survivors of 
operation, and ranged from 4 months to 18.2 years 
(median 6.5 years). At follow-up, functional results 
were rated as excellent in 77 patients (68.8%), good 
in 15 (13.4%), fair it! 15 (13.4%), and poor in 5 
(4.5%). Heartburn was present in 12 patients 
(10.7%), dysphagia in 11 (9.8%), bloating in seven 
(6.3%), regurgitation in four (3.6%), dumping in 
two (1.8%), and early satiety in one (0.9%). Four 
patients required postoperative dilatation after be- 
ing discharged from the hospital. 
Postoperative esophagogastroduoden0scopy was 
performed at least once in 72 patients (64.3%). Data 
from the most recent esophagogastroduodenoscopic 
examination revealed persistent BE in all patients. 
Additional abnormalities found in 28 patients in- 
cluded esophageal narrowing in 13, esophagitis in 
11, esophageal u cer in 10, adenocarcinoma in two, 
high-grade dysplasia in one, esophageal diverticu- 
lum in one, and recurrent hiatal hernia in one. In the 
patients with postoperative evidence of esophagitis 
or ulcer, it could be concluded that there was less 
than full protection from gastroduodenal reflux. 
Thirty-nine patients (34.8%) underwent an upper 
gastrointestinal barium swallow test after the ARP, 
which revealed esophageal stenosis in 10, recurrence 
of the diaphragmatic hernia in nine, and gastro- 
esophageal reflux in nine. 
The two patients with adenocarcinoma and the 
one with high-grade dysplasia underwent esopha- 
3 patients (2.7%) developed esophageal 
adenocarcinoma ~ 
E ~. 
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Fig. 1. Follow-up after ARP of 112 patients with BE. 
Arrows indicate time of diagnosis of adenocarcinoma after 
repair. 
geal resection; the latter patient was found to hav e 
carcinom~ in situ. All three of these patients were 
free of symptoms after ARP and were found to have 
specialized intestinal epithelium in esophageal bi- 
opsy samples after the ARP. Postsurgical stage was 
stage 0 (Tis NO M0) in one patient, stage I (T1 NO 
M0) in one, and stage liB (T1 N1 M0) in one, There 
was one perioperative death after esophageal resec- 
tion. Cause of death in this patient was rupture of 
the ~pulmonary artery during Swan-Ganz catheter 
placement. The second patient was aiive and well 2 
months after resection, but the third patient died of 
recurrent esophageal cancer at 15 months. Alto- 
gether, three patients (2.7%) had adenocarcinoma 
of the distal esophagus during follow-up at 13, 25, 
and 39 months after the ARP. Of interest, no 
patients acquired carcinoma fter 39 months, de- 
spite a median follow-up of 6.5 years and a maxi- 
mum follow-up of 18.2 years (Fig. 1). The incidence 
of adenocarcinoma among the 112 survivors of 
operation was one per 273.8 patient-years of follow- 
up. 
Discussion 
BE represents a carcinogenic process from benign 
squamous epithelium to metaplastic columnar epi- 
thelium and dysplasia and ultimately to invasive 
adenocarcinoma. Why some patients are at risk for 
BE is uncertain, but the pathophysiology clearly 
appears to involve reflux of gastric and duodenal 
contents. 14 Hopefully, further c|arification of the 
pathophysio!ogy will lead to ways to alter the pro- 
cess and prevent development of this complication 
and ultimately carcinoma. 
Prevention of symptoms of reflux by eliminating 
reflux of gastric and duodenal contents can be 
successfully accomplished with an ARP. Do ARPs 
result in regression of BE and reduction in the risk 
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of cancer, however? If so, when should patients 
undergo ARPs, and should mucosal ablation be 
added to ARPs? If not, how should these patients be 
followed up after ARPs? 
Regression of BE after ARPs has not been 
proved. Although sporadic ases of regression have 
been reported, 59 most studies, including this one, 
have failed to demonstrate regression after re- 
pair. 15-19 These observations suggest hat once BE 
becomes established, it is permanent. 
Equally important as regression of BE is the 
continued risk of dysplasia nd ultimately carcinoma 
after ARPs. Ideally, this risk would be eliminated 
after repair, but several studies have shown devel- 
opment of adenocarcinoma. 2°-23 Williamson and 
associates 23noted that three of 37 patients (8.1%) 
acquired carcinoma fter ARPs. Similarly, Stein and 
associates 2° reported on two patients who acquired 
adenocarcinoma at 50 and 106 months after ARPs, 
despite competent fundoplication as proved by man- 
ometric and pH monitoring. McCallum and col- 
leagues 21 noted that only 3.4% of their patients 
demonstrated progression toward dysplasia after 
ARPs, compared with 19.7% of those followed up 
after medical treatment. In our series of 112 survi- 
vors of operation, three acquired adenocarcinoma 
during follow-up, an incidence of one case per 273.8 
patient-years of observation. Of interest, all three of 
our patients acquired adenocarcinoma in the early 
follow-up period (less than 3.3 years), despite the 
fact that median follow-up was 6.5 years and ex- 
tended to 18.2 years. Where are the late cancers? 
Were these three adenocarcinomas occult at the time 
of the ARP and simply not detected? If this was 
indeed the situation, and no new cancers developed 
during late follow-up, these observations suggest pos- 
sibly that progression did not occur after an ARP. 
Because the risk of adenocarcinoma associated 
with BE continues to be present after an ARP, we 
currently recommend surveillance in these patients. 
Our practice is to obtain annual four-quadrant 
biopsy samples every 2 cm of the remaining BE. We 
hope that future advances, such as endoscopic ul- 
trasonography and molecular markers, may provide 
a method to identify mucosa t risk for transforma- 
tion into invasive carcinoma. It is also important o 
stress the need for follow-up objective reflux testing, 
which should include motility and 24-hour pH stud- 
ies, in these patients. Presence of reflux would 
suggest an incompetent ARP, and any protective 
effect would most likely be negated. 
If one accepts the pathophysiology of BE, when 
should one intervene with an ARP? Current medi- 
cal therapy reduces only the acid component of 
reflux. In contrast, a successful ARP can prevent 
reflux of both acid and duodenal contents. Recom- 
mendations for ARPs in patients with BE, however, 
have been similar to those for patients who have 
gastroesophagea! reflux problems without BE. 
Should patients with BE undergo an ARP at diag- 
nosis of BE, irrespective of symptoms? Although no 
convincing evidence xists to suggest hat BE will 
regress or that he development ofcarcinoma will be 
eliminated, our study surprisingly failed to demon- 
strate the development of adenocarcinoma in the 
late phase of follow-up: In addition, McCallum and 
associates 21noted that the incidence of dysplasia 
was less after an ARP than after medical treatment. 
These observations, if confirmed, would suggest that 
ARPs may be successful in preventing the develop- 
ment of new cancers. 
The benefits of early surgical intervention must be 
defined and weighed against he risk. In our review, 
risks were not insignificant and included an opera- 
tive mortality rate of 0.9% and a postoperative 
complication rate of 36.3%. Nearly one fourth of 
our patients had undergone previous esophageal 
operations, however, which undoubtedly increased 
risks of the current operation. Despite this, we are 
giving much stronger consideration to ARPs at 
diagnosis of BE than we had previously. Perhaps in 
the future the role of the taparoscopic ARP, if it 
withstands tile test of time, will be better defined. 
Also, if ablation of Barrett's mucosa after an ARP 
can be done successfully, this may be the most 
complete method of preventing the development of
cancer, a4 
In conclusion, patients with BE undergoing ARPs 
for reflux receive good long-term control of symp- 
toms. Despite this, the Barrett's mucosa and the 
ability for esophageal cancer to develop still exists. 
For this reason, we continue to recommend endo- 
scopic surveillance after repair. 
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Discussion 
Dr. Alex G. Little (Las Vegas, Nev.). First, I congratulate 
the program committee for starting the program with a 
presentation  the esophagus. I think an important point 
has been made, with all apologies to our president, hat 
the esophagus i the most important muscular pump in 
the chest. 
I also congratulate Dr. McDonald on an excellent 
presentation a d congratulate h r and her colleagues for 
making an important point about he relationships among 
BE, reflux, surgical control of reflux, and carcinoma. They 
have shown that patients continue to be at risk for 
development of adenocarcinoma after surgical control of 
reflux. The literature contains anecdotal reports that 
suggest the same conclusion, but to my knowledge this is 
the first time it has been based on a prospectively followed 
large group of patients who were operated on for symp- 
tomatic reflux, had BE, and were shown to acquire 
carcinoma fterward. So the important point, which cer- 
tainly should be recognized by surgeons and also I hope 
transmitted togastroenterologists, is t, hat patients need to 
be followed up after operation. 
I do have a few questions. I think that the presentation 
and the manuscript actually stop a little short of address- 
ing a few other issues that have been raised and could be 
answered. 
The first has to do with the definition of BE. Barrett 
described patients who had an ulcer in the midesophagus 
followed by 10 cm or more of columnar epithelium in the 
esophagus. You included patients with any amount of 
columnar epithelium "in the esophagus. I suggest that this 
is a broader criterion than most physicians would use, and 
it increases the denominator in your risk-factor analvsis 
considerably. Would you please comment on that? 
Dr. McDonald. We state in the Methods section that 
now we include if less than 3 cm if goblet cells are found 
on biopsy. 
Dr. Little. I accept hat, and I think the important thing 
is that you are very clear about it. but I think that it is a 
broader definition than many physicians would use. 
Second. for your three patients with carcinoma. I 
wonder whether you actually have proof, either clinically 
or ideally with some direct measurements, hat you did 
successfully curtail reflux in those patients. 
Dr. McDonald. Clinically, all three patients were free of 
symptoms after the ARP. On endoscopy, two patients had 
normal results and one had esophagitis. We did not do 
24-hour pH monitoring of those patients. 
Dr. Little. That is always the caveat hat comes up- -  
maybe those patients did not really get control of their 
reflux. I am seriously prepared to accept hat they did, but 
it is an important point. 
Also, all patients who went on to acquire carcinoma had 
specialized intestinal epithelium, and it is a common 
observation that essentially all patients with BE who get 
adenocarcinoma have this particular variant. Should such 
patients be treated more aggressively? Should they un- 
dergo resection? 
Dr. McDonald. That is among the future issues that 
need to be addressed, whether patients with specialized 
intestinal epithelium or patients with ulcers or strictures 
who are at higher risk should be treated more aggres- 
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sively. The answer to this question really is up in the air 
right now. What role laparoscopic Nissen mucosal abla- 
tion will have in future management remains to be seen. 
Dr. Little. The final question that obviously begs to be 
asked is what you think the role is for ARP in patients 
with BE. Is it only for control of symptoms, which I believe 
is a conclusion to be read into your article and one with 
which I agree, or would you suggest that there is a role for 
so,called prophylactic antireflux operations to prevent he 
development of adenocarcinoma? 
Dr. McDonald. f think that the ARP can halt the 
progression from Barrett's metaplasia to dysplasia to 
carcinoma. As ~ you noticed from our study, the three 
patients who did acquire cancer all did so very early, which 
leads t0 the question of whether these were just early 
carcinomas missed at the time of ARP. 
Dr. Little. I will conclude by saying that I think to some 
extent you are, trying to have it both ways. Patients with 
BE need to De monitored for the risk of cancer, yet this 
operation can prevent the developmgnt of cancer. It ought 
to be one way or the other. 
Dr. Arthur N. Thomas (San Francisco, Calif). I enjoyed 
your paper-very much, and this is an issue that I think all 
of us are seeing with increasing prominence. In my own 
practice, the prevalence of adenocarcinoma of the esoph- 
agus, particularly in the gastroesophageal junction region, 
has grown to maybe 60% to 80% of the people on whom 
we perform esophagectomy. I have a distinct impression 
that your group is atypical, for two reasons. One is that the 
patients with BE classically do not have a strong history of 
antireflux, and yours were intercepted quite quickly. Sec- 
ond, many of the medically treated patients were treated 
this way for a relatively brief time. The patients ! see with 
BE that undergoes malignant degeneration or evidences 
atypical mucosa have been treated with histamine block5 
ers or omeprazole for a number of years, and I would like 
you to comment on whether you think that prolonged 
medical therapy is related to this increased incidence of 
Carcinoma invo!ving BE. 
Dr. ,MeD0nald. You are right, most of our patients who 
were trea~ed medically were not treat~ed this way for a !ong 
period . Previous studies, have shown that medications by 
themselves do not halt the progression to carcinoma, so 
something further than just medical therap~ needs to be 
done. 
Dr. Thomas. Do you have ~any impressions regarding 
the'efficacy of surveillance by gastroenterologist s  n terms 
of detecting early carcinoma? 
Dr. McDonald. That all depends on your endoscopists 
and the number of biopsies you perform. If you have a 
good pathologist and you do four-quadrant biopsies every 
2 cm, you can be more accurate than people who are not 
doing a s thorough an endoscopic procedure. 
Dr. Thomas. The final question I would ask you is what 
you would consider premalignant; if it were yourself, 
would you want: an ARP or would you want to have the 
Barrett's epithelium removed in some more extensive 
procedure? 
Dr. McDonald. Anyone who has high-grade dysplasia 
should have the esophagus removed; for patients with 
low-grade dysplasia, we recommend medical management 
and biopsy every 3 months. 
Dr. Tom R. DeMeester (Los Angeles, Calif). I compli- 
ment Dr. McDonald on the quality of her presentation. 
Adenocarcinoma of the esophagus is the fastest rising 
cancer in the western world, having tripled in incidence 
stnce the 1970s. This presentation focuses on that issue. 
The only data available regarding the protective benefits 
of ARP were published by McCallum and associates. 21 
They reported on a registry of patients with BE who were 
free of dysplasia. Some were treated medically and others 
were treated surgically; they were followed up for about 5 
years. They showed that the incidence of dysplasia or 
cancer de~eloping was less in the surgical population. The 
study has been criticized because of ~he entrance criteria. 
For example, how extensively were these patients' tissues 
sampled for biopsy before entry to be sure that they were 
free of dysplasia? Consequently, this presentation could 
have a profound impact on the treatment of patients with 
BE. For this reason. I ask the following questions: 
First. it is important o be precise regarding the effec- 
tiveness of the repair in patients with BE who acquire 
cancer. If the message is that ARP does not protect 
against he development of cancer, the impact will be to 
limit the use of surgical therapy, even though it is the most 
effective anrireflux therapy. The report hat some patients 
had esophagitis uggests that the repair may not have 
been competent and that reflux continued, resulting in 
repetitive injury and progression of the BE to dysplasia 
and cancer. Our experience indicates that it is uncommon 
for us to operate on a patient with Barrett's adenocarci- 
noma who has had a previous competent ARP. I can 
count them on one hand. Yet we have operated on scores 
of patients with Barrett's adenocarcinoma who have been 
receiving long-term medical treatment. 
An important question is how many biopsy samples you 
require to exclude an early cancer before proceeding with 
ARP in someone with BE. How do you exclude the error 
of doing an ARP in the presence of an early carcinoma? 
Dr. McDonald. What we currently recommend is four- 
quadrant biopsy samples every 2 cm. and you also sample 
any suspicious area extensively. 
Dr. DeMeester. Did all of these patients undergo biopsy 
in that manner? 
Dr. McDonald. Yes, they did. 
Dr. DeMeester. BE can be end-stage reflux disease 
associated with decreased esophageal body contractility and 
a shortened esophagus from scarring. You seem to have 
taken the latter into consideration by doing a Collis gastro- 
plasty, but f am concerned about doing a full fundoplication 
in a patient who may have poor propulsion. I noticed that 
your dysphagia rate was about 11% and that your fair and 
poor results were around 20%. Do you think those results 
would improve if you did a partial fundoplication? 
Dr. McDonald. I do not know for sure whether we could 
have improved them. Currently, we obtain motility stud- 
ies, and if there is some evidence of dysfunction we alter 
our operation. The favored operation at Mayo in the past 
has been the uncut Collis-Nissen fundoplication, but we 
alter that operation if patients have abnormal peristalsis. 
Dr. DeMeester. So at present your philosophy is to alter 
the degree of fundoplication if there is a reduction in 
contraction amplitude? 
Dr. McDonald. Yes, it is. 
